Beckman Coulter Diagnostics and COPAN have announced that Beckman Coulter Diagnostics and COPAN Group have entered into an amendment to their distribution agreement that expands their relationship into new products and geographic territories.
Additional products include COPAN’s WASPLab automated, front‐end robotic specimen processing, full lab automation and digital microbiology system. The amendment grants Beckman Coulter distribution rights in 21 global markets, including a number of territories in North America, Asia (including, among other territories, Japan and China), Europe, South America and many emerging markets.
“We’re very excited to expand our relationship with COPAN to offer clinical microbiology
laboratories an extended portfolio of products to help provide physicians with the critical information they need regarding bacteria resistance,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics.
Kaldowski continued, “COPAN’s products complement our newly acquired MicroScan brand of microbiology solutions and offer hospitals and private laboratories a complete solution which streamlines workflow—demonstrating Beckman Coulter’s commitment to growth and investment in this new area of our business.”
Stefania Triva, COPAN Group’s CEO said, “This is a new step in the collaboration between the two companies and we look forward to continue working together to expand our reach.” Norman Sharples, Executive VP and Co‐Founder of COPAN Diagnostics, Inc. added, “COPAN has always been committed to provide open platform solutions to our customers and this partnership is further evidence and reinforcement of our ability to integrate and interface with important platforms in microbiology.”
In addition to WASPLab, the amendment allows Beckman Coulter to distribute COPAN’s CTracer, SYNAPSEPro MINI and MALDI‐Trace products.